By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.

Inside Moderna’s Biggest mRNA Test Since COVID

a16z General Partner Jorge Conde sits down with Moderna CEO Stéphane Bancel to discuss a major milestone for mRNA technology: positive Phase 3 results from Moderna and Merck’s individualized treatment for melanoma, after more than a decade…

Stéphane BancelguestJorge Condehost

Sep 2, 202638mWatch on YouTube ↗

Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.

CHAPTERS

Jump to publisher timestamps

Chapter summaries

Moderna’s claim: the first cancer vaccine to work (and why it matters)
Stéphane Bancel opens with a bold statement: after decades of failures, Moderna believes it has the first working cancer vaccine. The conversation tees up why this result is viewed as a turning point for therapeutic vaccines and personalized oncology.
- •Cancer vaccine field history: 20+ years and 1,000+ failed trials
- •Why a positive result would be a major inflection point for oncology
- •Core idea: retraining the immune system to recognize cancer
- •Sets up the questions of “what changed” and “how it works”
From COVID-era mRNA “machine” to Moderna’s next frontier: cancer
Host Jorge Conde reintroduces Moderna’s earlier COVID-19 mRNA success and frames this episode as the next major platform test. He positions the new melanoma results as evidence that mRNA manufacturing speed and programmability may translate beyond infectious disease.
- •Context: prior a16z episode on Moderna’s rapid COVID response
- •Why this August 2026 discussion is happening now: major cancer data
- •mRNA platform framing: analyze → design → ‘print’ medicines quickly
- •Preview of deep dives: trial results, personalization, operations, regulation
Phase 3 melanoma readout: vaccine + Keytruda beats Keytruda alone
Bancel explains the Phase 3 trial success with Merck, emphasizing recurrence-free survival and the surprise achievement of distant metastasis-free survival at interim analysis. He connects the Phase 3 announcement to earlier Phase 2 durability signals that suggest long-term disease-free outcomes.
- •Positive Phase 3 interim: met primary endpoint (recurrence-free survival)
- •Also met secondary endpoint (distant metastasis-free survival) earlier than expected
- •Positioning: first agent shown better than Keytruda alone in melanoma
- •Phase 2 context: ~80% disease-free at 5 years; 5 years often treated as ‘cure’ marker
- •Commercial intent: pushing for availability as early as 2027; factory readiness
What Keytruda does—and why it needs help
The discussion clarifies checkpoint inhibition in accessible terms: Keytruda “releases the brakes” on immune attack, but many patients still don’t benefit. Bancel highlights both non-response rates and serious autoimmune side effects as key reasons for combination approaches.
- •Keytruda as a PD-1 checkpoint inhibitor: ‘opens the gates’ for immune attack
- •Efficacy limitation: meaningful fraction (~40%) do not achieve long-term disease-free outcomes
- •Safety tradeoff: immune-related adverse events (type 1 diabetes, lupus, Crohn’s)
- •The unmet need: patients who get toxicity without benefit
- •Rationale for adding a more targeted immune ‘instruction’ layer
What “vaccine” means in cancer: preventing recurrence by teaching the immune system
Conde challenges the term “vaccine” since patients already have cancer; Bancel explains it as immune education rather than primary prevention. The goal is to train recognition of tumor-specific signals the immune system previously missed, reducing the chance of recurrence.
- •Therapeutic vaccine framing: preventing return of cancer, not initial cancer
- •Why the term persists: immune teaching parallels infectious disease vaccines
- •Baseline reality: cancer-like mutations arise continually; immunity usually clears them
- •Cancer progression as an immune recognition failure or evasion
- •Therapy objective: re-teach tumor recognition post-surgery/therapy
Why mRNA succeeded where prior cancer vaccines failed: delivery biology + personalization
Bancel attributes success to two factors: mRNA’s ability to drive antigen presentation inside key immune cells, and individualized target selection per patient. He contrasts this with prior protein/peptide approaches and “shared antigen” strategies that didn’t match the uniqueness of each tumor.
- •Two pillars: mRNA immunology advantage + individualized design
- •Moderna mRNA reaches lymph nodes and enters antigen-presenting cells (APCs)
- •Antigens produced/presented from within immune cells, not just circulating in blood
- •Historic limitation: proteins/peptides and shared antigens didn’t replicate this biology
- •Cancer as a DNA disease: individualized mutation signature is central
Inside the personalization pipeline: sequencing, mutation ranking, and 34 neoantigens
The episode details Moderna’s workflow: sequence tumor and normal DNA, compare letter-by-letter, and use algorithms to rank mutations for immune relevance. The top 34 are stitched into a single mRNA construct, creating a patient-specific immune training signal.
- •Inputs: tumor biopsy DNA + healthy cell DNA for matched comparison
- •Compute step: identify and prioritize relevant mutations among many
- •Design choice: select 34 neoantigens and encode them together in one mRNA
- •Manufacturing timeline: roughly ~30 days for construct creation (within broader workflow)
- •Key finding: ~90% of selected antigens differ across patients → personalization is essential
The ‘black box’ algorithm: data sources, partners, and why version 1.0 will improve
Conde presses on how the selection algorithm works; Bancel shares high-level components while protecting specifics. He frames today’s system as a decade-old “1.0” model and argues Phase 3 samples can help explain non-responders and drive iterative algorithm upgrades.
- •Built from public immunology/oncology knowledge plus proprietary internal datasets
- •Use of external partners with diagnostic/T-cell mapping datasets
- •Same algorithm used across Phases 1–3 (stability and validation)
- •Performance still leaves ~20% non-responders; focus shifts to understanding why
- •Plan: mine Phase 3 samples to refine algorithm (‘2.0’) with regulatory engagement
Operational reality of a vaccine-per-patient: robotics, footprint, and quality-first scaling
The conversation pivots from science to execution: how to reliably manufacture a unique injectable product for every individual. Bancel explains why early systems prioritized quality over efficiency, then shifted to shrinking machines, increasing throughput, and lowering cost once efficacy was clear.
- •Personalized manufacturing requires extreme process control and repeatability
- •Early strategy: build a ‘big fridge’ prototype optimized for quality, not efficiency
- •Avoiding false negatives: don’t let manufacturing imperfections undermine clinical truth
- •Post-Phase 2 pivot: engineer for throughput, automation, robotics, and smaller footprint
- •Two scaling levers: reduce cycle time and reduce clean-room square inches
Vein-to-vein (needle-to-needle) timing and how it differs from CAR-T
Conde asks about end-to-end turnaround time; Bancel cites ~42 days from biopsy to dose delivery. He argues this differs fundamentally from CAR-T because Moderna mostly ships information (sequence files), enabling a synthetic, enzymatic process with small reactors rather than ex vivo cell handling.
- •Current turnaround: ~42 days biopsy-to-vaccine (goal to improve)
- •Key distinction vs CAR-T: no need to extract/re-engineer/return live immune cells
- •mRNA as information: sequence file is the critical input
- •Synthetic enzymatic manufacturing resembles small-molecule-style processing
- •Smaller reactors and process design enable scalability improvements
Capacity, scale economics, and the open questions on COGS and pricing
Bancel discusses production capacity at Moderna’s Massachusetts facility and how improvements could expand throughput without new buildings. Pricing is left undecided pending full data disclosure and payer conversations, highlighting the economic complexity of individualized products.
- •Already produced thousands of doses across multiple ongoing studies
- •Marlborough facility target: tens of thousands of doses; sufficient for melanoma incidence
- •Throughput expected to rise with process improvements within same facility
- •Potential need for multiple facilities as indications expand
- •COGS/pricing not disclosed yet; dependent on data readouts and payer engagement
DIY ‘N-of-1’ cancer treatments vs industrialized personalization (and safety considerations)
Conde raises patient-led, bespoke treatment efforts; Bancel argues most will prefer an industrial provider due to contamination risk and process reliability. He emphasizes GMP validation and standardized quality as critical when injecting products into patients.
- •Expectation: most patients will use established manufacturers rather than DIY paths
- •Injection safety risks: contamination can cause sepsis; multi-step processes can fail
- •GMP validation reduces risk and improves reproducibility
- •Analogy: early necessity to self-make tools fades once high-quality supply exists
- •Industrialization frees patients to focus energy elsewhere
Regulating a medicine that changes every time: process-based approval pathway
The regulatory discussion centers on approving the end-to-end process rather than each unique dose, similar to CAR-T precedents. Bancel describes long-running FDA engagement from IND onward and frames the key requirement as consistent outputs from identical inputs.
- •Precedent: CAR-T approvals; pathway is process BLA, not product-by-product approval
- •IND and manufacturing discussions started years earlier; ongoing FDA engagement
- •Regulatory focus: robustness—same input samples should yield same final product
- •Includes manufacturing protocol control and reproducibility across individualized runs
- •Not a ‘new surprise’ to regulators; extensive iterative education and Q&A occurred
Beyond melanoma: three expansion strategies across cancer types
Bancel lays out a roadmap for broader oncology impact, centered on where PD-1 therapy already works, earlier-stage disease where checkpoint toxicity limits use, and ‘hard’ tumors where checkpoints fail. He also points to future combinations with other targeted therapies.
- •Vector 1: combine where Keytruda already works (lung Phase 3; kidney/bladder Phase 2)
- •Vector 2: earlier-stage disease with intratumoral monotherapy (e.g., stage 1 lung)
- •Rationale: avoid checkpoint autoimmune toxicities in low-stage patients
- •Vector 3: checkpoint-resistant cancers (pancreatic, gastric) as high-risk experiments
- •Future: orthogonal combos (e.g., with KRAS-targeted drugs) may amplify benefit
The platform arc: infectious disease → cancer → genetic disease and autoimmune ambitions
In closing, the conversation broadens to Moderna’s platform trajectory: COVID validated speed and scale, cancer validates individualized immune programming, and next targets include rare genetic liver diseases and autoimmune conditions. Bancel hints at both “one product for all” and individualized autoimmune approaches.
- •Near-term: pivotal late-stage study expected for rare pediatric genetic liver disease
- •Platform learning: deepening immune-system know-how from infectious disease and cancer
- •New frontier: autoimmune disease—aiming to treat root causes, not just symptoms
- •Two approaches: non-personalized autoimmune products and individualized immune targeting
- •Teaser for future: personalized modulation to eliminate misbehaving immune cells

Publisher timestamps

Get more out of YouTube videos.

Read along on your phone, search it beside the video, or ask your favorite AI app what was said.